Live cell evaluation of granzyme delivery and death receptor signaling in tumor cells targeted by human natural killer cells

Blood

Volumn 126, Issue 8, 2015, Pages e1-e10

  Vrazo, Alexandra C ^a   Hontz, Adrianne E ^a   Figueira, Sarah K ^a   Butler, Braeden L ^b   Ferrell, Julie M ^a   Binkowski, Brock F ^b   Li, Jinzhu ^a   Risma, Kimberly A ^a,c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b PROMEGA CORPORATION   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMMONIA LYASE; CASPASE; CASPASE 3; CASPASE 7; DEATH RECEPTOR; FAS LIGAND; FC RECEPTOR; GRANZYME; GRANZYME A; GRANZYME B; GRANZYME K; INTERLEUKIN 2; LUCIFERASE; PERFORIN; PROTEINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN;

ARTICLE; BIOSENSOR; BIOTECHNOLOGY; CELL DEATH; CONJUGATION; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; EFFECTOR CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; JURKAT CELL LINE; K562 CELL LINE; NATURAL KILLER CELL; PRIMARY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; SIGNAL TRANSDUCTION; TARGET CELL; TUMOR CELL; APOPTOSIS; FLOW CYTOMETRY; GENETIC PROCEDURES; GENETIC TRANSFECTION; IMMUNOBLOTTING; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE;

APOPTOSIS; BIOSENSING TECHNIQUES; CASPASES; CELL LINE, TUMOR; ENZYME ACTIVATION; FLOW CYTOMETRY; GRANZYMES; HUMANS; IMMUNOBLOTTING; IMMUNOTHERAPY; JURKAT CELLS; K562 CELLS; KILLER CELLS, NATURAL; NEOPLASMS; RECOMBINANT PROTEINS; TRANSFECTION;

EID: 84940021026     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-03-632273     Document Type: Article

References (64)

1. Chowdhury D, Lieberman J. Death by a thousand cuts: granzyme pathways of programmed cell death. Annu Rev Immunol. 2008;26:389-420.
2. Susanto O, Trapani JA, Brasacchio D. Controversies in granzyme biology. Tissue Antigens. 2012;80(6):477-487.
3. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol. 1996;24(3):406-415.
4. Yamamoto K, Shibata F, Miyasaka N, Miura O. The human perforin gene is a direct target of STAT4 activated by IL-12 in NK cells. Biochem Biophys Res Commun. 2002;297(5):1245-1252.
5. Carayol G, Robin C, Bourhis JH, et al. NK cells differentiated from bone marrow, cord blood and peripheral blood stem cells exhibit similar phenotype and functions. Eur J Immunol. 1998;28(6):1991-2002.
6. Liu CC, Rafii S, Granelli-Piperno A, Trapani JA, Young JD. Perforin and serine esterase gene expression in stimulated human T cells. Kinetics, mitogen requirements, and effects of cyclosporin A. JExpMed. 1989;170(6):2105-2118.
7. Fehniger TA, Cai SF, Cao X, et al. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity. 2007;26(6):798-811.
8. Lopez JA, Susanto O, Jenkins MR, et al. Perforin forms transient pores on the target cell plasma membrane to facilitate rapid access of granzymes during killer cell attack. Blood. 2013;121(14):2659-2668.
9. Metkar SS, Wang B, Ebbs ML, et al. Granzyme B activates procaspase-3 which signals a mitochondrial amplification loop for maximal apoptosis. J Cell Biol. 2003;160(6):875-885.
10. Sutton VR, Wowk ME, Cancilla M, Trapani JA. Caspase activation by granzyme B is indirect, and caspase autoprocessing requires the release of proapoptotic mitochondrial factors. Immunity. 2003;18(3):319-329.
11. Andrade F, Roy S, Nicholson D, Thornberry N, Rosen A, Casciola-Rosen L. Granzyme B directly and efficiently cleaves several downstream caspase substrates: implications for CTL-induced apoptosis. Immunity. 1998;8(4):451-460.
12. McIlwain DR, Berger T, Mak TW. Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol. 2013;5(4):a008656.
13. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med. 1998;188(12):2375-2380.
14. Screpanti V, Wallin RP, Grandien A, Ljunggren HG. Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. Mol Immunol. 2005;42(4):495-499.
15. Eischen CM, Schilling JD, Lynch DH, Krammer PH, Leibson PJ. Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J Immunol. 1996;156(8):2693-2699.
16. Sheard MA, Asgharzadeh S, Liu Y, et al. Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells. J Immunother. 2013;36(5):319-329.
17. Montel AH, Bochan MR, Hobbs JA, Lynch DH, Brahmi Z. Fas involvement in cytotoxicity mediated by human NK cells. Cell Immunol. 1995;166(2):236-246.
18. Crowder RN, El-Deiry WS. Caspase-8 regulation of TRAIL-mediated cell death. Exp Oncol. 2012;34(3):160-164.
19. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol. 2008;26(21):3621-3630.
20. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5(2):157-163.
21. Sprick MR, Rieser E, Stahl H, Grosse-Wilde A, Weigand MA, Walczak H. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J. 2002;21(17):4520-4530.
22. Biesinger B, Müller-Fleckenstein I, Simmer B, et al. Stable growth transformation of human T lymphocytes by herpesvirus saimiri. Proc Natl Acad Sci USA. 1992;89(7):3116-3119.
23. Li J, Figueira SK, Vrazo AC, et al. Real-time detection of CTL function reveals distinct patterns of caspase activation mediated by Fas versus granzyme B. J Immunol. 2014;193(2):519-528.
24. Williams DA, Tao W, Yang F, et al. Dominant negative mutation of the hematopoietic-specific Rho GTPase, Rac2, is associated with a human phagocyte immunodeficiency. Blood. 2000;96(5):1646-1654.
25. Van Damme P, Maurer-Stroh S, Hao H, et al. The substrate specificity profile of human granzyme A. Biol Chem. 2010;391(8):983-997.
26. Hirata Y, Inagaki H, Shimizu T, et al. Expression of enzymatically active human granzyme 3 in Escherichia coli for analysis of its substrate specificity. Arch Biochem Biophys. 2006;446(1):35-43.
27. Fan F, Binkowski BF, Butler BL, Stecha PF, Lewis MK, Wood KV. Novel genetically encoded biosensors using firefly luciferase. ACS Chem Biol. 2008;3(6):346-351.
28. Brennan AJ, Chia J, Browne KA, et al. Protection from endogenous perforin: glycans and the C terminus regulate exocytic trafficking in cytotoxic lymphocytes. Immunity. 2011;34(6):879-892.
29. Galbán S, Jeon YH, Bowman BM, et al. Imaging proteolytic activity in live cells and animal models. PLoS One. 2013;8(6):e66248.
30. Bade B, Boettcher HE, Lohrmann J, et al. Differential expression of the granzymes A, K and M and perforin in human peripheral blood lymphocytes. Int Immunol. 2005;17(11):1419-1428.
31. Bovenschen N, Quadir R, van den Berg AL, et al. Granzyme K displays highly restricted substrate specificity that only partially overlaps with granzyme A. J Biol Chem. 2009;284(6):3504-3512.
32. Shi L, Kam CM, Powers JC, Aebersold R, Greenberg AH. Purification of three cytotoxic lymphocyte granule serine proteases that induce apoptosis through distinct substrate and target cell interactions. J Exp Med. 1992;176(6):1521-1529.
33. Mori S, Itoh Y, Shinohata R, Sendo T, Oishi R, Nishibori M. Nafamostat mesilate is an extremely potent inhibitor of human tryptase. J Pharmacol Sci. 2003;92(4):420-423.
34. Poe M, Wu JK, Blake JT, Zweerink HJ, Sigal NH. The enzymatic activity of human cytotoxic T-lymphocyte granzyme A and cytolysis mediated by cytotoxic T-lymphocytes are potently inhibited by a synthetic antiprotease, FUT-175. Arch Biochem Biophys. 1991;284(1):215-218.
35. Shivakumar P, Mourya R, Bezerra JA. Perforin and granzymes work in synergy to mediate cholangiocyte injury in experimental biliary atresia. J Hepatol. 2014;60(2):370-376.
36. Legrand F, Driss V, Delbeke M, et al. Human eosinophils exert TNF-α and granzyme A-mediated tumoricidal activity toward colon carcinoma cells. J Immunol. 2010;185(12):7443-7451.
37. Yagita M, Huang CL, Umehara H, et al. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia. 2000;14(5):922-930.
38. Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8(4):652-658.
39. Suck G, Branch DR, Smyth MJ, et al. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. Exp Hematol. 2005;33(10):1160-1171.
40. Jiang W, Chai NR, Maric D, Bielekova B. Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis. J Immunol. 2011;187(2):781-790.
41. Caserta TM, Smith AN, Gultice AD, Reedy MA, Brown TL. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis. 2003;8(4):345-352.
42. Willoughby CA, Bull HG, Garcia-Calvo M, Jiang J, Chapman KT, Thornberry NA. Discovery of potent, selective human granzyme B inhibitors that inhibit CTL mediated apoptosis. Bioorg Med Chem Lett. 2002;12(16):2197-2200.
43. Caligiuri MA, Murray C, Robertson MJ, et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest. 1993;91(1):123-132.
44. Molleran Lee S, Villanueva J, Sumegi J, et al. Characterisation of diverse PRF1 mutations leading to decreased natural killer cell activity in North American families with haemophagocytic lymphohistiocytosis. J Med Genet. 2004;41(2):137-144.
45. Mellor-Heineke S, Villanueva J, Jordan MB, et al. Elevated Granzyme B in Cytotoxic Lymphocytes is a Signature of Immune Activation in Hemophagocytic Lymphohistiocytosis. Front Immunol. 2013;4(72):72.
46. Dybkaer K, Iqbal J, Zhou G, et al. Genome wide transcriptional analysis of resting and IL2 activated human natural killer cells: gene expression signatures indicative of novel molecular signaling pathways. BMC Genomics. 2007;8(230):230.
47. Pon RA, Freedman MS. Study of Herpesvirus saimiri immortalization of gammadelta T cells derived from peripheral blood and CSF of multiple sclerosis patients. J Neuroimmunol. 2003;139(1-2):119-132.
48. Owen-Schaub LB, Yonehara S, Crump WL III, Grimm EA. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell Immunol. 1992;140(1):197-205.
49. Owen-Schaub LB, Zhang W, Cusack JC, et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol. 1995;15(6):3032-3040.
50. Simon AK, Williams O, Mongkolsapaya J, et al. Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: sensitivity of human thymocytes. Proc Natl Acad Sci USA. 2001;98(9):5158-5163.
51. Hietakangas V, Poukkula M, Heiskanen KM, Karvinen JT, Sistonen L, Eriksson JE. Erythroid differentiation sensitizes K562 leukemia cells to TRAIL-induced apoptosis by downregulation of c-FLIP. Mol Cell Biol. 2003;23(4):1278-1291.
52. Reid GSD, Bharya S, Klingemann HG, Schultz KR. Differential killing of pre-B acute lymphoblastic leukaemia cells by activated NK cells and the NK-92 ci cell line. Clin Exp Immunol. 2002;129(2):265-271.
53. Jenkins MR, Rudd-Schmidt JA, Lopez JA, et al. Failed CTL/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. J Exp Med. 2015;212(3):307-317.
54. Hoff BA, Chughtai K, Jeon YH, et al. Multimodality imaging of tumor and bone response in a mouse model of bony metastasis. Transl Oncol. 2012;5(6):415-421.
55. Hink-Schauer C, Estébanez-Perpiñá E, Kurschus FC, Bode W, Jenne DE. Crystal structure of the apoptosis-inducing human granzyme A dimer. Nat Struct Biol. 2003;10(7):535-540.
56. Hink-Schauer C, Estébanez-Perpiñá E, Wilharm E, et al. The 2.2-A crystal structure of human progranzyme K reveals a rigid zymogen with unusual features. J Biol Chem. 2002;277(52):50923-50933.
57. Lieberman J. Granzyme A activates another way to die. Immunol Rev. 2010;235(1):93-104.
58. Yamamoto M, Saigo K, Koshiba M, et al. Inhibition of natural killer cytotoxicity in vitro by clinical grade serine protease inhibitors. Haematologia (Budap). 2002;32(2):103-111.
59. Susanto O, Stewart SE, Voskoboinik I, et al. Mouse granzyme A induces a novel death with writhing morphology that is mechanistically distinct from granzyme B-induced apoptosis. Cell Death Differ. 2013;20(9):1183-1193.
60. Pardo J, Bosque A, Brehm R, et al. Apoptotic pathways are selectively activated by granzyme A and/or granzyme B in CTL-mediated target cell lysis. J Cell Biol. 2004;167(3):457-468.
61. Munker R, Marini F, Jiang S, Savary C, Owen-Schaub L, Andreeff M. Expression of CD95(FAS) by gene transfer does not sensitize K562 to Faskilling. Hematol Cell Ther. 1997;39(2):75-78.
62. McGahon AJ, Nishioka WK, Martin SJ, Mahboubi A, Cotter TG, Green DR. Regulation of the Fas apoptotic cell death pathway by Abl. J Biol Chem. 1995;270(38):22625-22631.
63. Hao J-H, Yu M, Liu F-T, Newland AC, Jia L. Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells. Cancer Res. 2004;64(10):3607-3616.
64. Jia L, Patwari Y, Srinivasula SM, et al. Bax translocation is crucial for the sensitivity of leukaemic cells to etoposide-induced apoptosis. Oncogene. 2001;20(35):4817-4826.